Background and Purpose: Corneal injury can result in dysfunction of corneal nociceptive signaling and corneal sensitization. Activation of the endocannabinoid system has been reported to be analgesic and anti-inflammatory. The purpose of this research was to investigate the antinociceptive and anti-inflammatory effects of cannabinoids with reported actions at cannabinoid 1 (CB 1 R) and cannabinoid 2 (CB 2 R) receptors and/or noncannabinoid receptors in an experimental model of corneal hyperalgesia. Methods: Corneal hyperalgesia (increased pain response) was generated using chemical cauterization of the corneal epithelium in wild-type (WT) and CB 2 R knockout (CB 2 R À/À ) mice. Cauterized eyes were treated topically with the phytocannabinoids D THC, but not CBD, were blocked by the CB 1 R antagonist AM251, but were still apparent, for both cannabinoids, in CB 2 R À/À mice. However, the antinociceptive and anti-inflammatory actions of HU-308 were absent in the CB 2 R À/À mice. The antinociceptive and anti-inflammatory effects of CBD were blocked by the 5-HT 1A antagonist WAY100635. Conclusion: Topical cannabinoids reduce corneal hyperalgesia and inflammation. The antinociceptive and anti-inflammatory effects of D 8 THC are mediated primarily via CB 1 R, whereas that of the cannabinoids CBD and HU-308, involve activation of 5-HT 1A receptors and CB 2 Rs, respectively. Cannabinoids could be a novel clinical therapy for corneal pain and inflammation resulting from ocular surface injury.
Introduction
The cornea is a thin, transparent dome-shaped avascular tissue that is densely innervated by sensory nerve endings. 1, 2 Damage to these nerve endings, resulting from surgery, trauma, neurological disease, or infection, may develop into corneal neuropathic pain (CNP). 2 CNP is a clinically significant problem characterized by persistent hyperalgesia, debilitating pain, photoallodynia, burning, stinging, dryness, and inflammation. 3 Corneal damage can also result in an inflammatory response that involves the production of proinflammatory cytokines, neovascularization, recruitment of leukocytes, and release of neuropeptides producing inflammatory pain. 4, 5 Existing pharmacotherapies for ocular pain, inflammation, and CNP include topical corticosteroids, tricyclic antidepressants, GABAergic drugs, and opioids. 3, 6 These treatments, however, frequently fail to provide adequate pain relief and are associated with side effects. 3, 6 Therefore, new therapies that can alleviate pain and symptoms associated with CNP have fewer side effects and can resolve corneal inflammation are urgently required. One drug target that may have a role in the modulation of pain and inflammation is the endocannabinoid system (ECS). 7, 8 The ECS is an endogenous lipid signaling system that includes two G-protein-coupled receptors, cannabinoid 1 receptor (CB 1 R) and cannabinoid 2 receptor (CB 2 R), endocannabinoids, and cognate enzymes for biosynthesis and degradation of endocannabinoids. 9, 10 CB 1 Rs are widely expressed in many tissues, including in the central and peripheral nervous systems, where activation of CB 1 R modulates neurotransmitter release, and nerve activity.
11,12 CB 2 R is highly expressed on immune cells and its activation is anti-inflammatory, resulting in decreased production of proinflammatory mediators and a reduction in leukocyte recruitment. [13] [14] [15] Drugs that enhance activation of the ECS, including activation of both CB 1 R and CB 2 R, have shown efficacy in experimental models of pain and inflammation, including neuropathic pain. 7, 9, 16, 17 Cannabinoids have not been extensively studied in ocular surface pain and inflammation; however, CB 1 R is expressed in the corneal epithelium and endothelium in rodents and primates, 18 and activation of CB 1 R has been reported to inhibit neuropeptide-induced sensitization of transient receptor potential cation channel subfamily V member 1 (TRPV1) in afferent neurons.
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Under nonpathological conditions, CB 2 R expression is low in the cornea and anterior ocular structures; however, increased CB 2 R expression in anterior ocular tissues has been suggested in experimental uveitis, where CB 2 R activation produces anti-inflammatory effects. [19] [20] [21] Taken together, these studies suggest that cannabinoids that activate CB 1 R and/or CB 2 R may be useful for mitigating corneal pain and inflammation.
In this study, we used a mouse model of corneal hyperalgesia to investigate the antinociceptive and anti-inflammatory effects of several cannabinoids that act at CB 1 R and/or CB 2 [22] [23] [24] [25] [26] CBD lacks the behavioral effects of THC at CB 1 R, and may produce pharmacological actions through the activation of noncannabinoid receptors. [27] [28] [29] HU-308 is a selective and highly potent agonist at CB 2 R, 30 and has previously been shown to reduce lipopolysaccharideinduced intraocular inflammation. 19 
Materials and Methods
Experimental animals and corneal injury model All animal care and experimental procedures complied with the Canadian Council for Animal Care guidelines (www.ccac.ca/) and were approved by the Dalhousie University Committee on Laboratory Animals. Male BALB/c (20-30 g; Charles River Laboratories International, Inc., Wilmington, MA) and CB 2 R knockout mice (CB 2 R À/À ) were used for experiments. CB 2 R À/À mice were obtained by crossing male C57BL/6J CB 2 R À/À mice (strain B6.129P2-Cnr2tm1Dgen/J; Jackson Laboratory, Bar Harbor, ME) with inbred BALB/c female mice (Charles River) for 10 generations. Genetic loss of CB 2 R (Cnr2) was confirmed via polymerase chain reaction genotyping using DNA extracted from ear punches with an Accustart II Mouse Genotyping Kit (Quanta Biosciences, Gaithersburg, MD) according to the manufacturer's instructions. Primer sequences were as follows: mouse CB 2 mutant forward (moIMR0086) 5¢-GGG GAT CGA TCC GTC CTG TAA GTC T-3¢; mouse CB 2 wild-type (WT) forward (oIMR7552) 5¢-GGA GTT CAA CCC CAT GAA GGA GTA C-3¢; mouse CB 2 common reverse (oIMR7552) 5¢-GAC TAG AGC TTT GTA GGT AGG CGG GÀ3¢ with a single product at *550 bp for CB 2 R À/À , a single product at *385 bp for WT, and two products at *550 and 385 bp for heterozygous mice. Mice were housed in groups of 3-5, kept on a light/dark cycle (07:00-19:00/19:00-07:00), and fed ad libitum.
Corneal injury was induced using a protocol adapted from a model of corneal hyperalgesia previously described in rats by Wenk and Honda. 31 Briefly, mice were anesthetized using 2-3% isoflurane gas. The center of the cornea on both eyes was cauterized with silver nitrate (MedPro Ò , 75% silver nitrate, 25% potassium nitrate; AMG Medical Inc., Montreal, QC, Canada) using a micro-applicator brush (Centrix, Inc., Shelton, CT). The micro-applicator brush was held in contact with the cornea for 2 sec, producing a distinct superficial white lesion of 1 mm in diameter, injuring the epithelial cell layer only. The cauterized eyes were then rinsed with saline and an ocular lubricant (Systane Ò ; Alcon Canada, Inc., Dorval, QC, Canada) was applied to reduce corneal drying. Mice recovered fully from anesthesia within 3-5 min postcauterization. Mice were euthanized at 6 or 12 h postcauterization, and the eyes were enucleated for immunohistochemical analysis.
Assessment of behavioral pain sensitization At 6 or 12 h postcauterization, 5 lL of 1 lM capsaicin was applied topically to the cauterized eyes to elicit a pain response. 32 A sham control group was induced by touching the micro-applicator brush to the cornea for 2 sec in the absence of sliver nitrate, keeping all other parameters the same. Immediately following the application of a single dose of capsaicin, the behavioral response was video recorded for 30 sec. Videos were analyzed offline in slow motion, where the number of blinks, squints, and eye wipes to capsaicin challenge was summed to give a pain score.
Immunohistochemistry
At 12 h following corneal cauterization, eyes were enucleated and fixed in 4% PFA, followed by 30% sucrose overnight. Corneal sections (12 lm) were cut using a Leica CM1850 cryostat (Wetzlar, Germany). Sections were washed in phosphate-buffered saline (PBS) and blocked for nonspecific binding (10% normal goat serum in 0.5% Triton-X/PBS; Sigma-Aldrich, Oakville, ON, Canada) for 2 h, followed by a 48-h incubation in purified rat anti-Ly-6G antibody (1:200; Abcam, Cambridge, MA). Ly-6G is a glycosylphosphatidylinositolanchor protein expressed predominantly on neutrophils; the anti-Ly-6G antibody allows for detection of these cells. 33 Sections were then washed with PBS and incubated with a secondary antibody (1:500, goat anti-rat Alexa Fluor Ò 488, Jackson ImmunoResearch Laboratories, Inc., West Grove, PA). Stained sections were washed in PBS and mounted on Superfrost slides (Fisher Scientific, ON, Canada) using Fluoromount (Sigma-Aldrich).
Neutrophil migration, indicative of an innate immune response, was quantified in corneal sections at 20 · magnification using a Zeiss Axiovert 200 M microscope (Zeiss, Thornwood, NY). Three representative images were taken from each section of the right and left corneal peripheries and from the center of the cornea, respectively. The total number of neutrophils from these three images was counted for each section, and summed to represent the total neutrophil number for a single corneal section. A total of 5-12 sections with 120 lM intervals from each eye were analyzed and the neutrophil number was averaged. 
Drugs and solutions
D 8 THC ([6aR,10aR]-6,6,9-trimethyl-3-pentyl- 6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol; Cayman Chemical, Ann Arbor, MI), CBD (2-[(1R,6R)-3- Methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5- pentyl-1,3-benzenediol; Cayman Chemical), HU-308 (4-[4-(1,1-Dimethylheptyl)-2,6-dimethoxyphenyl]-6,6- dimethylbicyclo[3.1.1]hept-2-
Data analysis
Individual animals in each treatment group were coded and experimental data were analyzed blinded. One-way analysis of variance (ANOVA) with Dunnett's or Tukey's multiple comparison post hoc tests was used, as appropriate, to compare data between experimental groups of three or more. t-Tests were used to compare two experimental groups. The number of animals in each group was 5-12. All data reported are represented as group mean -standard deviation. Data were considered significant at p < 0.05.
Results

Corneal chemical injury results in hyperalgesia and inflammation
At 6 h, the pain score to 1 lM capsaicin was significantly increased in cauterized eyes (20 -7, n = 10) compared to sham control (11 -4, n = 6; p < 0.01). At 12 h, no significant difference ( p > 0.05) was observed in pain score between sham control animals (7 -3, n = 5) compared to cauterized eyes (12 -3, n = 6). In addition, the pain score in cauterized eyes at 12 h was significantly lower than the pain score at 6 h ( p < 0.05; Fig. 1A ).
Immunohistochemical analysis was carried out to examine neutrophil migration, indicative of an inflammatory response, in the cornea 6 and 12 h after capsaicin challenge in either cauterized or sham eyes. Neutrophils were not observed in sham control corneas at 12 h (Fig. 1C) . Figure 1B demonstrates, however, the presence of neutrophils at 6 and 12 h following cauterization (126 -33, n = 5, and 156 -28, n = 6, respectively; THC, CBD, and HU-308 were examined in WT mice to establish the effective drug concentrations required to reduce corneal pain compared to the vehicle-treated group (Fig. 2A) . Administration of 0.5% and 1% D 8 THC produced a significant reduction in pain scores (18 -6, n = 6, p < 0.05; 12 -5, n = 12, p < 0.0001, respectively). Although at lower concentrations (0.2% and 0.4%) D 8 THC did not significantly affect the pain score (n = 6 in each group; p > 0.05). Topical application of 5% CBD also significantly reduced the pain score (15 -3, n = 10, p < 0.001); however, 3% CBD was not effective at reducing the pain score (n = 6, p > 0.05). In addition, while 1% HU-308 did not produce a significant reduction in pain score (n = 6, p > 0.05), administration of 1.5% HU-308 was antinociceptive (17 -4, n = 6, p < 0.01). Therefore, given their efficacy at reducing the pain response, 1% D 8 THC, 5% CBD, and 1.5% HU-308 were used for all further experiments.
Neutrophil infiltration into the cornea following treatment with cannabinoids was examined. Topical administration of 1% D Fig. 3A ; n = 8, p > 0.05), suggesting that D 8 THC acts via CB 1 R to reduce corneal pain. However, the antinociceptive actions of 5% CBD were maintained in eyes pretreated with CB 1 R antagonist AM251 (23 -6, n = 8), compared to vehicle-treated eyes plus AM251 (35 -4, n = 8, p < 0.001; Fig. 3A) .
Likewise, the number of neutrophils in corneas from mice treated with AM251 and either 1% D The antinociceptive and anti-inflammatory effects of HU-308, but not D 8 THC or CBD, were mediated through CB 2 R The involvement of CB 2 R in the antinocicpetive and anti-inflammatory effects of D 8 THC, CBD, and HU-308 was examined using CB 2 R À/À mice. Compared to WT mice receiving vehicle, the mean number of neutrophils in vehicle-treated CB 2 R À/À mice was significantly increased (mean difference 102 -30, n = 6 and 7, respectively, p < 0.01); however, there was no significant difference in the pain score (n = 8 in each group, p > 0.05).
In CB 2 R À/À mice at 6 h postcauterization, compared to vehicle-treated eyes (27 -7, n = 8), application of 1% D 8 THC (8 -5, n = 12) or 5% CBD (19 -4, n = 7) significantly decreased the pain score ( p < 0.0001 and p < 0.05, respectively). However, the antinociceptive effect of 1.5% HU-308 (n = 7) was not significantly different compared to vehicle-treated animals ( p > 0.05; Fig. 4A ), confirming the involvement of CB 2 R in the antinociceptive effects of HU-308, but not THC or CBD.
Consistently, at 12 h postcauterization in CB 2 R À/À mice, the number of neutrophils in corneas receiving either 1% D 8 THC (123 -50, n = 6) or 5% CBD (187 -28, n = 6) was significantly less than vehicletreated corneas (307 -71, n = 7; p < 0.0001 and p < 0.01, respectively). In HU-308-treated corneas (1.5%) from CB 2 R À/À mice (n = 6), there was no significant difference in neutrophil numbers compared to vehicle-treated eyes ( p > 0.05; Fig. 4B ).
CBD acts at 5-HT 1A receptors to reduce corneal pain and inflammation
The corneal antinociceptive and anti-inflammatory effects of CBD were independent of CB 1 R or CB 2 R. Therefore, we examined an alternative non-cannabinoid receptor, 5-HT 1A , which has been reported as a target for CBD in other tissues. 29 Treatment of mice with the 5-HT 1A receptor antagonist WAY100635 (1.0 mg/kg i.p.) was able to completely eliminate the antinociceptive actions of CBD in cauterized cornea ( Fig. 5A ; n = 8 in each group, p > 0.05). In mice treated with WAY100635, the reduction in corneal neutrophils in cauterized eyes seen with CBD treatment was also blocked (n = 6 in each group, p > 0.05), suggesting that 5-HT 1A is the target receptor for CBD-mediated antinociceptive and anti-inflammatory actions in the cornea (Fig. 5B ).
Discussion
Our results provide novel evidence that the phytocannabinoids D 8 THC and CBD and synthetic cannabinoid derivative HU-308 are antinociceptive and anti-inflammatory in an experimental model of corneal hyperalgesia. Furthermore, we demonstrate that the actions of these cannabinoids are mediated via distinct receptor targets that include CB 1 R and CB 2 R, as well as 5-HT 1A receptor.
In the mammalian cornea, expression of CB 1 R has been reported to colocalize with TRPV1, 34 the latter of which is expressed in corneal epithelium 35 and endothelium, 36 and sensory nerve endings of the ophthalmic branch of the trigeminal nerve innervating the cornea. 37 TRPV1 is activated following damage to cornea, culminating in activation of corneal nerves and local inflammation. The release of proinflammatory cytokines and neuropeptides, including nerve growth factor and substance P, contributes to neurogenic inflammation and can lead to corneal nerve sensitization. 34, 38 In sensory neurons isolated from rat dorsal root ganglia, activation of CB 1 R by the cannabinoid agonist ACEA (arachidonoyl-2¢-chloroethylamide) prevented nerve growth factor-induced sensitization of the TRPV1 receptor. This action was blocked by the CB 1 R antagonist AM251, suggesting that the THC (n = 6), 5% CBD (n = 6), or 1.5% HU-308 (n = 6). Values represent mean -SD. For statistical analysis, one-way ANOVA with Dunnett's post hoc test (compared to vehicle) was used. ****p < 0.0001, **p < 0.01, *p < 0.05. CB 2 R, cannabinoid 2 receptor. activation of CB 1 R may produce analgesia by desensitization of TRPV1 receptors. 39 Our results demonstrating that topical D 8 THC, acting at CB 1 R, reduces hyperalgesia following corneal injury are in line with these findings. In addition, we also demonstrated that D 8 THC was able to reduce the neutrophil recruitment to the cornea observed at later time points following corneal epithelial damage. The inhibition of neutrophil recruitment was blocked with the treatment of CB 1 R antagonist AM251, but was still present in CB 2 R À/À mice. This suggests that the activation of CB 1 R by D 8 THC is important in mitigating the innate immune response following corneal injury, which may contribute to corneal nerve sensitization.
The importance of peripheral CB 1 R in our study is also consistent with the actions of D 9 THC reported in other models of both acute inflammatory and neuropathic pain. For example, administration of D 9 THC (1 mg/kg i.p.) in a rat model of acute muscle pain produced antinociceptive effects, which was blocked by the CB 1 R antagonist AM281 and to a lesser extent by the CB 2 R antagonist AM630 (0.5 mg/kg i.p.). 40 Furthermore, in a model of inflammatory and neuropathic pain, mice lacking CB 1 R in peripheral nociceptive neurons showed a reduced analgesic effect to local and systemic administration of the cannabinoid WIN55,212-2. With intrathecal application, the analgesic effect of WIN55,212-2 was absent, suggesting that peripheral CB 1 R in nociceptive neurons plays an important role in producing the analgesic effects of cannabinoids. 41 Our data implicate 5-HT 1A receptors, and not cannabinoid receptors, in both antinociceptive and antiinflammatory actions of CBD in an experimental model of corneal injury. We showed that the actions of CBD were completely blocked by the 5-HT 1A antagonist WAY100635, but were still present after CB 1 R block or in CB 2 R À/À mice. CBD has been reported in other in vitro and in vivo models to bind to 5-HT 1A receptors. 27, 29, 42 Using a heterologous cell expression system, Russo et al. reported that CBD bound to both human and rat 5-HT 1A receptors with micromolar affinity, and displaced the agonist [
3 H]8-OH-DPAT in a concentration-dependent manner. 29 In addition, CBD increased [ 35 S]GTPcS binding, and decreased forskolinstimulated cAMP production, which was blocked by the specific 5-HT 1A antagonist In line with our findings of CBD activity at the 5-HT 1A receptor, a study by Ward et al. reported that CBD administration could prevent chemotherapy-induced neuropathic pain associated with paclitaxel treatment. 43 In this study, CBD was administered chronically for 14 days and prevented the onset of paclitaxel-induced mechanical and thermal sensitivity in female mice. A subsequent report showed that a subchronic dosing regimen of 2.5-10 mg/kg CBD (i.p.) was also effective in preventing paclitaxel-induced mechanical sensitivity. This effect was blocked by a 5-HT 1A antagonist (WAY100635), but not a CB 1 R (SR141716) or CB 2 R antagonist (SR144528), further supporting the role of 5-HT 1A in mediating the actions of CBD in preventing neuropathic pain. 43 HU-308 has been reported as a selective CB 2 R agonist. 30 In our model of corneal hyperalgesia, the antinociceptive and anti-inflammatory actions of HU-308, unlike D 8 THC and CBD, were absent in CB 2 R À/À mice, validating target specificity for this cannabinoid at CB 2 R. This is the first time a CB 2 R agonist has been demonstrated to reduce corneal pain, although CB 2 R activation has been reported to reduce ocular inflammation. 20, 44 In experimental uveitis, Toguri et al. 19 reported that CB 2 R activation reduced leukocyte/endothelial adhesion in the iridial microvasculature as well as inhibited release of proinflammatory mediators, including TNFa, IL1b, Il6, CCL5, and CXCL2. Conversely, a CB 2 R antagonist, AM630, increased leukocyte/endothelial adhesion in experimental uveitis, 19 suggesting that CB 2 R activity in the eye is immunosuppressive during inflammation. In a mouse model of proliferative vitreoretinopathy, CB 2 R À/À or pharmacological block of CB 2 R, also produced increased inflammation and a more severe pathology. 44 Another study, in a mouse model of endotoxemia, has shown increased neutrophil recruitment to the spleen in CB 2 R À/À mice compared to WT control. 45 In line with these results, in our experiments we observed an increase in the mean number of neutrophils in cauterized corneas in CB 2 R À/À mice, suggesting that loss of constitutive CB 2 R activity is proinflammatory in ocular tissues. 20, 44 Reports of the antinociceptive and antiallodynic efficacy of CB 2 R agonists have also been reported in other experimental models of hyperalgesia and chronic inflammatory neuropathic pain. 46 While our study in cornea used a relatively acute dosing regimen, the utility of CB 2 R agonists used chronically was previously reported in a mouse model of paclitaxel-induced neuropathic pain. 47 The authors reported that chronic CB 2 R activation with the CB 2 R-preferring agonist AM1710 was able to reverse paclitaxel-induced allodynia, an effect that was blocked in WT mice treated with the CB 2 R antagonist AM630, or in CB 2 R À/À mice. In comparison to repeated dosing with agonists such as THC that produced behavioral effects and tolerance via CB 1 R activation, no similar effects were observed with the CB 2 R-preferring agonist AM1710. Furthermore, using intrathecal cannabinoid administration, this study identified a possible role for spinal CB 2 R in the antiallodynic actions of AM1710, as well as a reduction in proinflammatory cytokines, in paclitaxel-treated mice. 47 Increased CB 2 R expression has also been reported in human peripheral nerves after injury, and CB 2 R agonist-mediated inhibition of capsaicin responses was observed in cultured human dorsal root ganglion sensory neurons. 48 Our data demonstrating the antinociceptive and anti-inflammatory actions of CB 2 R activation in cornea, together with these studies, further support the utility of CB 2 R agonists for treating inflammatory pain.
Conclusion
Our study showed that topical application of the phytocannabinoids D 8 THC and CBD, and the cannabinoid derivative HU-308, reduced corneal hyperalgesia and neutrophil infiltration resulting from superficial chemical injury of corneal epithelium. The effects of these cannabinoids were mediated by distinct receptors, including CB 1 R and CB 2 R, as well as 5-HT 1A receptors. This suggests that when used either as sole agents or in combination, these cannabinoids could be effective agents in the treatment of ocular pain and inflammation resulting from corneal surface injuries.
